Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Antonio, Texas 78215


The primary objective of this study is to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) ± ribavirin (RBV) in participants with chronic genotype 1 hepatitis C virus (HCV) infection and prior treatment experience with a direct acting antiviral (DAA).


Key Inclusion Criteria: - Individuals with chronic HCV genotype 1 infection - Documented as treatment experienced with a direct acting antiviral-containing regimen without achieving sustained viral response - Absence of cirrhosis or presence of compensated cirrhosis - Screening laboratory values within defined thresholds - Must use specific contraceptive methods if female of childbearing potential or sexually active male Key Exclusion Criteria: - Co-infection with HIV or hepatitis B virus (HBV) - Current or prior history of clinical hepatic decompensation - Chronic use of systemic immunosuppressive agents - History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol - Pregnant or a nursing female Note: Other protocol defined Inclusion/Exclusion criteria may apply.



Primary Contact:

Study Director
Gilead Study Director
Gilead Sciences

Backup Contact:


Location Contact:

San Antonio, Texas 78215
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.